Journey Medical DERM
NASDAQ DERM
$5.22 +0.05 (+0.97%)
At close: Oct 20, 2026 · 4:00 PM EDT

Journey Medical (DERM) EBITDA Margin (2020)

Updated

Journey Medical's EBITDA Margin came in at -51.29% for FY2021, down 72.12 percentage points from 20.83% in FY2020.

Analysis

Journey Medical (DERM) EBITDA Margin (2020) Analysis & Trends

  • Per Business Quant, earlier years put EBITDA Margin at 20.83% in FY2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,146.94 Bn 1,115.53 Bn 19.71 Bn 53.49%
2 Johnson & Johnson 624.96 Bn 543.49 Bn 17.26 Bn 35.95%
3 AbbVie 510.15 Bn 483.27 Bn 12.70 Bn 49.01%
4 Merck 366.13 Bn 320.51 Bn 12.21 Bn 6.02%
5 Novartis Ag 297.75 Bn 261.74 Bn 11.24 Bn -
6 Astrazeneca 261.93 Bn 235.62 Bn 12.86 Bn 33.11%
7 Amgen 236.51 Bn 191.91 Bn 7.24 Bn 46.01%
8 Gilead Sciences 194.27 Bn 168.47 Bn 6.22 Bn -124.26%
9 Pfizer 171.74 Bn 118.39 Bn 10.94 Bn 39.16%
10 Journey Medical 144.34 Mn 42.43 Mn 12.37 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2020 28.76%
Sep 30, 2020 6.77%
API Access

Journey Medical EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=DERM&period=max&api_key=YOUR_API_KEY